|
?:abstract
|
-
Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose With the advance of COVID-19 and the pandemic declaration;It has become the closest alternative to reduce the advance of the virus Antimalarial, antiviral drugs, antibiotics, glucocorticoids, monoclonal antibodies, among others, are being studied;their findings, although preliminary, could establish a starting point in the search for a solution In this review, we present a selection of drugs, of different classes and with potential activity against COVID-19, whose trials are ongoing;and as proofs of concept, double blind, add-on event-driven, would allow proposing research that generates results in less time and preserving quality criteria for drug development and approval by regulatory agencies Resumen El drug repositioning, es una estrategia que identifica nuevos usos de medicamentos aprobados, para tratar condiciones diferentes a las de su propósito original Con el avance del COVID-19 y la declaración de pandemia;se ha convertido en la alternativa más cercana para frenar el avance del virus Fármacos antimalariales, antivirales, antibióticos, glucocorticoides, anticuerpos monoclonales entre otros están siendo estudiados;sus hallazgos, aunque preliminares, podrían establecer un punto de partida en la búsqueda de la solución En este artículo, se presenta una selección de fármacos, de distinta clase y con potencial actividad para combatir al COVID-19, cuyos ensayos se encuentran en curso;y como las prueba de concepto, double blind, add-on event-driven, permitirían proponer investigaciones que generen resultados en menor tiempo y conservando los criterios de calidad para el desarrollo de medicamentos y su aprobación por las agencias reguladoras
-
Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. With the advance of COVID-19 and the pandemic declaration; It has become the closest alternative to reduce the advance of the virus. Antimalarial, antiviral drugs, antibiotics, glucocorticoids, monoclonal antibodies, among others, are being studied; their findings, although preliminary, could establish a starting point in the search for a solution. In this review, we present a selection of drugs, of different classes and with potential activity against COVID-19, whose trials are ongoing; and as proofs of concept, double blind, add-on event-driven, would allow proposing research that generates results in less time and preserving quality criteria for drug development and approval by regulatory agencies.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}